Foghorn Therapeutics (FHTX) Change in Cash (2019 - 2026)
Foghorn Therapeutics (FHTX) posted quarterly Change in Cash of $6.8 million for Q1 2026, up 21.81% year-over-year from $5.6 million in Q1 2025, and up 180.24% quarter-over-quarter from -$8.5 million in Q4 2025.
Analysis
Foghorn Therapeutics (FHTX) Change in Cash (2019 - 2026) Analysis & Trends
Foghorn Therapeutics' Change in Cash history runs 8 years deep, the most recent figure standing at $6.8 million for Q1 2026.
- In Q1 2026, Change in Cash rose 21.81% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $28.2 million (up 254.6% YoY), while the FY2025 annual figure was $27.0 million, up 208.37% from the prior year.
- Change in Cash for Q1 2026 stood at $6.8 million, up from -$8.5 million in the prior quarter.
- The five-year high for Change in Cash was $112.5 million in Q1 2022, with the low at -$152.4 million in Q2 2022.
- The 5-year median for Change in Cash is $6.8 million (2026), against an average of -$703294.1.
- Peak annual rise in Change in Cash reached 745.28% in 2024, while the deepest fall reached 744.84% in 2024.
- Foghorn Therapeutics' Change in Cash stood at -$35.4 million in 2022, then surged by 128.32% to $10.0 million in 2023, then tumbled by 122.17% to -$2.2 million in 2024, then tumbled by 280.31% to -$8.5 million in 2025, then jumped by 180.24% to $6.8 million in 2026.
- Business Quant data shows FHTX's Change in Cash at $6.8 million in Q1 2026, -$8.5 million in Q4 2025, and $16.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | -185.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 427.25 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | -2.94 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | -37.42 Mn |
| 10 | Foghorn Therapeutics | 347.50 Mn | 279.42 Mn | - | -20.83 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -20.83 Mn |
| Mar 31, 2026 | 6.79 Mn |
| Dec 31, 2025 | -8.46 Mn |
| Sep 30, 2025 | 16.76 Mn |
| Jun 30, 2025 | 13.09 Mn |
| Mar 31, 2025 | 5.57 Mn |
| Dec 31, 2024 | -2.22 Mn |
| Sep 30, 2024 | -81.27 Mn |
| Jun 30, 2024 | 59.69 Mn |
| Mar 31, 2024 | -1.08 Mn |
| Dec 31, 2023 | 10.03 Mn |
| Sep 30, 2023 | 12.60 Mn |
| Jun 30, 2023 | 7.06 Mn |
| Mar 31, 2023 | -1.57 Mn |
| Dec 31, 2022 | -35.42 Mn |
| Sep 30, 2022 | 26.40 Mn |
| Jun 30, 2022 | -152.44 Mn |
| Mar 31, 2022 | 112.51 Mn |
| Dec 31, 2021 | 43.30 Mn |
| Sep 30, 2021 | -67.33 Mn |